Great Debates in HIV Care

1.00 CME
$0 FEE


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.

Activity Description

This CME activity, "Great Debates in HIV Care," features discussion and debate among worldwide experts from a practical and clinically relevant perspective about critical and potentially controversial issues in the care of patients with HIV. Antiretroviral therapy (ART) has improved dramatically over the past decade, and this progress has yielded more treatment choices for clinicians and patients. However, it also adds greater complexity to the already diverse field of HIV. In this interactive, case-based program, expert faculty provide guidance on how to incorporate new treatment strategies into clinical practice and discuss various aspects of HIV management, including selecting an initial antiretroviral regimen, clarifying the differences in tenofovir alafenamide and tenofovir disoproxil fumarate in antiretroviral therapeutic regimens, considering cardiovascular disease and diabetes in the management of patients with HIV, switching ART, and managing treatment in women.

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the treatment of patients with human immunodeficiency virus (HIV).

Learning Objective(s)

Upon successful completion of this educational activity, participants should be better able to:

  • Assess new clinical evidence about conventional and newer antiretroviral treatment regimens for HIV, including ongoing research.
  • Apply updated guidelines to improve the overall management of patients with HIV.
  • Assess the differences in safety and efficacy between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in antiretroviral therapeutic regimens.
  • Implement best practices to reduce risk factors and manage chronic comorbidities in patients with HIV.
  • Incorporate measures that improve the individualized management of HIV in newly diagnosed patients, women, and those with comorbidities.

Activity Chair

Richard A. Elion, MD
Director of Clinical Research
Washington Health Institute
Clinical Professor of Medicine
George Washington University School of Medicine
Washington, DC


Grace A. McComsey, MD, FIDSA
Vice President of Research and Associate Chief Scientific Officer
University Hospitals Health System
Director, University Hospitals Clinical Research Center
Director, Dahms Clinical Research Unit John Kennell Endowed Chair
Chief, Pediatric Infectious Diseases and Rheumatology
Professor of Pediatrics and Medicine
Case Western Reserve University
Cleveland, OH

Graeme J. Moyle, MD, MBBS, DipGUM
Director of HIV Research Strategy
Chelsea and Westminster Hospital
London, United Kingdom

Babafemi O. Taiwo, MBBS
Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, IL

David A. Wohl, MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill
School of Medicine
Chapel Hill, NC


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 30, 2019, through December 29, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate. 


MIPS Qualifying Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of the Quality Payment Program (QPP), accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. 

Activity Chair and Faculty report the following relationship(s)

Richard A. Elion, MD
Consulting Fees: Gilead, ViiV
Speakers Bureau: Gilead, ViiV
Contracted Research: Gilead, Trio Health, ViiV

Grace A. McComsey, MD, FIDSA
Consulting Fees: Gilead, Merck, ViiV

Graeme J. Moyle, MD, MBBS, DipGUM
Consulting Fees: Gilead, Merck, Theratechnologies, ViiV
Speakers Bureau: Gilead, Merck
Contracted Research: Amgen, Gilead, Merck

Babafemi O. Taiwo, MBBS
Consulting Fees: Gilead, GlaxoSmithKline, Merck, ViiV

David A. Wohl, MD
Consulting Fees: Gilead, Janssen, Merck, ViiV
Contracted Research: Gilead, Merck, ViiV

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at